Observational Connectomics in Adults Undergoing Resection of WHO II-IV Glioma
A Prospective, Longitudinal, Multi-Institutional, Observational Study to Correlate Quantitative Changes of the Human Structural and Functional Connectome in Adults Undergoing Neurosurgical Resection of WHO II-IV Glioma
This observational study will create a large scale database (registry) of glioma patients' data across multiple participating institutions (hospitals) to study a range of clinical research questions.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The Glioma Connectome Project (GCP) is a study that seeks to use safe, powerful, non-invasive computing tools of machine learning and artificial intelligence, to take information from the functional MRI resting state (rs-fMRI) and the anatomic MRI using diffusion-weighted MRI to develop a comprehensive map of the brain. This "Virtual Brain" in the future may assist neurosurgeons in planning glioma surgery, understanding the cause of neurological deficits caused by the tumor, and a road map to help avert postoperative deficits, while also monitoring recovery of neurological function, as the brain "heals" or reorganizes itself through neuroplasticity.
The information from your MRI will be analyzed using algorithms to produce a map of the key tracts, functional hubs, and connections in the brain in terms of seven major networks: sensorimotor, visual, central executive (CEN), default mode (DMN), salience, dorsal attention (DAN) and limbic system. The completion of the project will advance diagnostics, brain imaging, brain tumor surgery, and provide the basis for new tools and drugs to treat brain injury and accelerate recovery of neurological function lost to the tumor, and treatments for the tumor, including surgery, radiation, chemotherapy.
The registry is being created to evaluate new computer-based technology that builds on ourknowledge of the human brain through the Glioma Connectome Project, which discovered that the brain could be divided into 180 areas per hemisphere or "parcellations", each with a function that is achieved by signaling other areas, forming broad networks, which influence brain function and brain health. Seven major networks are of great interest as they influence human neurological performance. These networks will be identified in the current study, throughout the course of the treatment for your glioma, by using the advanced neuroimaging which is standard of care at Lenox Hill Hospital.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Tamika Wong, MPH
- Número de teléfono: 212-434-4836
- Correo electrónico: twong4@northwell.edu
Copia de seguridad de contactos de estudio
- Nombre: Randy D'Amico, MD
- Número de teléfono: 212-434-3900
- Correo electrónico: rdamico8@northwell.edu
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10075
- Reclutamiento
- Lenox Hill Brain Tumor Center
-
Sub-Investigador:
- David Langer, MD
-
Sub-Investigador:
- Tamika Wong, MPH
-
Investigador principal:
- Randy D'Amico, MD
-
Sub-Investigador:
- John Boockvar, MD
-
Sub-Investigador:
- Olivia Albers, NP
-
Contacto:
- Randy D'Amico, MD
- Número de teléfono: 212-434-3900
- Correo electrónico: rdamico8@northwell.edu
-
Contacto:
- Tamik Wong, MPH
- Número de teléfono: 212-434-4836
- Correo electrónico: twong4@northwell.edu
-
Sub-Investigador:
- Netanel Ben-Shalom, MD, FNPS
-
Sub-Investigador:
- Taylor Winby, NP
-
Sub-Investigador:
- Elizabeth Lepski, NP
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Newly diagnosed and recurrent glioma (WHO grade II, III, IV) undergoing surgery
Descripción
Inclusion Criteria:
- Age > 18 years.
- Newly diagnosed patients (by MRI) suspected of having a brain tumor (WHO II,III, or IV) who will undergo surgery with histological confirmation or patients undergoing surgery for recurrent brain tumor (WHO grades II, III, IV) whose histology confirms glioma and/or treatment effect.
- Diffuse astrocytomas, multifocal gliomas, oligodendrogliomas, midline and brainstem gliomas are included.
- Previously treated (progressive, recurrent) gliomas are included. Thus, prior surgery, radiation therapy, anti-angiogenic therapy, electrical field therapy are not exclusions.
- Patient must be able to give informed consent. S/he must be able to read and understand English or there must be a qualified interpreter.
- Must be able to undergo sequential MRI in a facility that can perform 30-directional MRI for connectomic analyses.
Exclusion Criteria:
- Juvenile pilocytic glioma (WHO I)
- Histology that is non-glioma, e.g., brain metastases, craniopharyngioma, ependymoma, medulloblastoma, meningioma, lymphoma, tumefactive (demyelinative) plaque, abscess, germinoma, arachnoid cyst, epidermoid, PXA, DNET, ganglioglioma, central neurocytoma,
- Inability to give informed consent.
- Tissue samples obtained at surgery are insufficient/ or non-diagnostic for glioma
- Expected survival < 90 days due to primary disease or medical co-morbidities. (e.g. sepsis, pneumonia, organ failure)
- Inability to have a MRI due to cardiac pacemaker, implants, claustrophobia, allergy to gadolinium,
- Pregnancy. Because of potential risk of serial MRI to fetus, women of child-bearing age will need a pregnancy test and agree to contraceptive practices during the course of the study.
- Vulnerable population
- Medications. There are no restrictions on medications. Patients will receive best standard of care.
- Clinical Trials. Patients may also be enrolled in a clinical trial as a clinical trial is always recommended for patients with a glioma per NCCN guidelines.
- KPS < 40.
- Age < 17.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Newly diagnosed or recurrent glioma (WH) II, III, or IV)
Newly diagnosed patients (by MRI) suspected of having a glioma (WHO II,III, or IV) who will undergo surgery with histological confirmation or patients undergoing surgery for recurrent glioma (WHO grades II, III, IV) whose histology confirms glioma and/or treatment effect. |
Advanced MRI imaging done preoperatively, immediately following surgery, one month after surgery, and 3 months after surgery, then every 2 to 3 months for the duration of the study. These images are being done as standard of care and include functional MRI resting state (rs-fMRI) and the anatomic MRI using diffusion-weighted MRI to develop a comprehensive map of the brain.
Otros nombres:
Neuropsychological test that will be administered on an iPad, and should take no more than one hour to complete. Subjects will first complete a mini mental state exam to assess their mental status. This will only take 5-10 minutes to complete. Based on the results they may undergo all or some of the following neuropsychological tests which will be completed on an iPad:
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Connectomic Metrics
Periodo de tiempo: From enrollment up to 5 years.
|
FWHM (Full width-Half maximum) |
From enrollment up to 5 years.
|
|
Connectomic Metrics
Periodo de tiempo: From enrollment up to 5 years.
|
Network index |
From enrollment up to 5 years.
|
|
Connectomic Metrics
Periodo de tiempo: From enrollment up to 5 years.
|
Betweenness centrality (the value of each node to the whole network, defined by the fraction of the shortest paths passing through this node to all shortest paths that do not pass through it) |
From enrollment up to 5 years.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
KPS
Periodo de tiempo: From enrollment up to 5 years.
|
The KPS describes a patient's functional status as a comprehensive 11-point scale correlating to percentage values ranging from 100% (no evidence of disease, no symptoms) to 0% (death). Each percentage reflects the patient's ability to perform daily activities and their level of independence or care needs. For instance, 100% indicates full independence, while 10% describes a moribund state with rapid disease progression. |
From enrollment up to 5 years.
|
|
Progression-free survival
Periodo de tiempo: From enrollment up to 5 years.
|
Progression-free survival (PFS) is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease without it getting worse, growing, or spreading |
From enrollment up to 5 years.
|
|
Overall survival (OS)
Periodo de tiempo: From enrollment up to 5 years.
|
Overall survival (OS) is the length of time from either the date of diagnosis or the start of a treatment until death from any cause. |
From enrollment up to 5 years.
|
|
Molecular markers and drivers of glioma growth
Periodo de tiempo: From enrollment up to 5 years.
|
IDH mutational status, MGMT, ki-67, EGFR, p53, ATRX, TERT promoter, 1p19q chromosomal deletions, extent of resection, length of hospital stay |
From enrollment up to 5 years.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Randy D'Amico, MD, Northwell Health
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Neoplasias Neuroepiteliales
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Glioblastoma
- Glioma
- Astrocitoma
- Disciplinas y actividades de comportamiento
- Pruebas psicológicas
- Pruebas neuropsicológicas
Otros números de identificación del estudio
- 24-0143
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Clinical Data from the other study centers part of the Glioma Connectome Project (GCP) will be transferred pseudonymously.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .